Market News AIOpen the app

Summit Therapeutics Inc.: Other Events (SMMT)

TrialRead the original at SEC EDGAR
Bad for SMMT

The FDA said Summit's application cannot be approved because the study did not show that patients lived longer. The study did delay cancer worsening, and later results suggested longer survival, but the FDA said those results were not enough.

SMMT · Summit Therapeutics Inc.

AI read · Bad for SMMT

The AI's read

Summit is left without approval for this treatment in the patient group named in the application. The study delayed cancer worsening, and later follow-up suggested longer survival. But the main survival result did not show a reliable increase in how long patients lived, so the positive results were not enough for the FDA.

Get alerts for SMMT

Follow Summit Therapeutics Inc. (SMMT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SMMT
Free on the App Store and Google Play, or on the web.